Arcutis Eyes Atopic Dermatitis Opportunity With Ducentis Buy

Paying Just $16m Upfront In Cash For UK Biotech

 
• By Kevin Grogan
  
Magnet
The attraction of Arcutis proves strong for Ducentis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip